Well, so much for the big rally in Sequenom shares. The stock, which jumped by more than 20 percent Monday on rumors of extremely positive data on its Down syndrome test, fell by nearly 14 percent today as the rumors failed to materialize. The shares are up a smidgen in after-hours trading.

We’ve taken a particular interest in San Diego-based Sequenom’s shares since late April when it was revealed that company employees mishandled in-house trial data on the test, which could revolutionize how pregnant women are tested for the presence of Down syndrome in their babies.


Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.